Skip to content

Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study)

Association of Sonographic Glandular Tissue Component With Breast Cancer Risk Among Women With Dense Breasts: A Prospective, Multinational Validation Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05460975
Enrollment
16164
Registered
2022-07-15
Start date
2022-11-01
Completion date
2031-12-30
Last updated
2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Screening

Keywords

Breast cancer, Dense breast, Risk factors, Ultrasonography

Brief summary

An international multicenter study to prospectively validate the association between sonographic GTC and subsequent breast cancer risk in women with dense breasts.

Detailed description

Women with similarly dense breasts on mammography may have different subsequent risks of developing breast cancer due to varying degrees of lobular involution. Breast ultrasound (US) can assess the relative amount of glandular tissue component (GTC) to the fibrous stroma in dense breast parenchyma and can reflect the amount of terminal duct lobular units (TDLU) as seen in histology. In women with dense breasts on mammography, an association between high levels of sonographic GTC, defined as the percent of glandular tissue within fibroglandular tissue, and an increased risk of breast cancer was demonstrated in a retrospective single-center study of 8483 Korean women. The purpose of this international multicenter study is to prospectively validate whether sonographic GTC is associated with subsequent breast cancer risk and whether it can provide additional information beyond established risk factors. In this study, investigators will enroll 16164 women with dense breasts (BI-RADS density categories C and D on mammography) undergoing screening breast US using either an automated or handheld device. GTC will be assessed qualitatively as minimal, mild, moderate, or marked at the time of US interpretation and will be dichotomized into low (minimal or mild) versus high (moderate or marked). The primary outcome is a pathologic diagnosis of breast cancer, including invasive cancer and ductal carcinoma in situ (DCIS). Women are observed from 3 months after date of GTC assessment to breast cancer diagnosis or censoring as a result of death or end date of complete cancer capture. Covariate information will be obtained from self-report at the time of breast US examination and includes age, race/ethnicity, menopausal status, first-degree family history of breast cancer, breast density, history of benign breast biopsy, BMI, age at first live birth, and hormone replacement therapy (HRT) usage. The 5-year cumulative incidence of breast cancer by level of sonographic GTC will be compared based on marginal standardization with the predicted risk summed to a weighted risk according to the observed covariate distribution in the study population. The association of sonographic GTC with breast cancer risk will be estimated by using the Fine-Gray subdistribution hazards model to account for the competing risk of death. In addition, investigators will compare the discriminatory accuracy of the breast cancer surveillance consortium (BCSC) 5-year risk score and the BCSC model integrated with sonographic GTC.

Interventions

None listed

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 69 Years

Inclusion criteria

1. be ≥ 40 and \<70 years old at time of US 2. No history of previous breast cancer including DCIS 3. have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2) 4. undergoing screening breast US using either automated or handheld device

Exclusion criteria

1. history of bilateral prophylactic mastectomy 2. history of bilateral foreign body injection 3. history of bilateral breast implants 4. history of bilateral breast reduction surgery or surgical excision 5. currently pregnant or breast feeding in the preceding 6 months 6. Known distant metastasis from other primary cancer

Design outcomes

Primary

MeasureTime frameDescription
Incident breast cancer within 3 months to 7 years after the assessment of sonographic GTCfrom 3 months to 7 years after the GTC assessmentThe 5-year cumulative incidence of breast cancer and hazard ratio by level of sonographic GTC using standardized risk

Secondary

MeasureTime frameDescription
Correlation of sonographic GTC with risk according to tumor typefrom 3 months to 7 years after the GTC assessmentCorrelation of sonographic GTC with risk according to tumor type (DCIS vs. invasive cancer)
Correlation of sonographic GTC with breast cancer according to the breast US devicefrom 3 months to 7 years after the GTC assessmentCorrelation of sonographic GTC with breast cancer according to the breast US device (hand-held vs. automated)
The expected-to-observed (E/O) number of cancer diagnoses and concordance index (discriminatory accuracy)from 3 months to 7 years after the GTC assessmentThe expected-to-observed (E/O) number of cancer diagnoses and concordance index (discriminatory accuracy) for the BCSC model (5-year risk score) and BCSC model integrated with sonographic GTC
Breast US diagnostic performance according to sonographic GTCfrom the examination till 1 year after the GTC assessmentSensitivity, specificity, positive predictive value

Countries

South Korea

Contacts

Primary ContactWoo Kyung Moon, MD, PhD
moonwk1963@gmail.com+82220722584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026